scAAV-Cre (AAV Serotype 4, Self-complementary)

What it means: Promoter is the DNA regulatory element that drives transcription of the AAV payload. The promoter listed here is CMV.

How to interpret here: Use CMV to predict where and how strongly your transgene will be expressed. Promoters vary in strength, cell-type preference, and long-term stability in different tissues. CMV is a strong, broadly active viral promoter often used for high expression, but activity can vary by cell type and can be reduced in some in vivo contexts over time. Expression regulation is listed as Constitutive—this affects whether expression is always on vs controlled by a system/design. Cell-type intent is Ubiquitous—promoter choice is one of the main drivers of specificity, but serotype and delivery route also shape which cells are transduced. Serotype is AAV2/4—capsid tropism can limit which cells ever receive the genome, even with a broadly active promoter. Transgene is Cre—very high expression of some payloads can be toxic or confounding, so promoter strength should match your biology. Listed applications: In vivo gene delivery, Cre/loxP recombination, Conditional genetics, Lineage tracing. If your goal is in vivo work, consider promoter suitability for your tissue and timeline.

Why it matters for buying:

• Specificity: Promoter choice is the main lever for restricting expression to certain cell types (when possible).
• Signal level: Promoter strength influences detectability, functional effect size, and risk of overexpression artifacts.
• Design constraints: Promoter size competes with payload size inside AAV packaging limits, which can force trade-offs.

Practical guidance:

• Match promoter to tissue: Choose promoters with known performance in your tissue/model (especially for in vivo brain work).
• Plan validation: Confirm expression pattern with a reporter or immunostaining early (pilot cohort) before committing to a large study.
• Consider immune/silencing effects: Some promoters can behave differently over time in vivo—monitor expression at the timepoints you care about.

What to watch out for:

• Promoter ≠ tropism: A promoter can’t drive expression in cells that aren’t transduced; serotype/route still control delivery.
• Context dependence: Promoter activity can change with developmental stage, disease state, or inflammation.
• Overexpression: Very strong promoters can produce non-physiologic levels—interpret phenotypes with dose and controls.

Handling note:

• Form: Frozen liquid — plan thawing/mixing accordingly and avoid repeated freeze-thaw where possible.
• Buffer: PBS — confirm compatibility with your injection/assay buffer requirements.
• Storage: -80°C — aliquot on first thaw when feasible to preserve titer/activity.

What it means: Transgene is the gene payload carried by the AAV genome (the coding sequence or functional cassette). The transgene listed here is Cre.

How to interpret here: Use Cre to determine what biological function you’re introducing (overexpression, recombinase, reporter, sensor, or control). The same serotype/promoter can behave very differently depending on payload biology. Cre recombinase is used for Cre/lox conditional genetics; ensure your model carries a compatible floxed allele or reporter. Function category is Recombinases—use this to sanity-check that the payload matches your experimental intent. Promoter is CMV—promoter strength and specificity control where the transgene is expressed. Expression regulation is Constitutive—verify whether your design expects constitutive vs regulated expression. Sensor/actuator field is Cre—if the payload requires light/ligand/guide RNAs, ensure you have the complementary components and controls. Cellular localization is Nuclear—confirm it matches your assay readout (nuclear vs cytosolic vs membrane).

Why it matters for buying:

• Biological relevance: The transgene defines the mechanism you’re testing—incorrect payload choice can invalidate the study design.
• Assay compatibility: Some payloads require specific detection, stimulation, or genetic context (e.g., Cre/lox).
• Safety and artifacts: High expression or active enzymes can stress cells; dose and controls matter.

Practical guidance:

• Confirm compatibility: For recombinases/editors, verify your model (floxed allele/reporter) and any required guide RNA or helper systems.
• Plan a pilot: Validate expression and basic function (timecourse, dose range) before committing to large cohorts.
• Use matched controls: Include a null/control vector and/or a reporter-only control to separate delivery effects from payload effects.

What to watch out for:

• Payload-dependent toxicity: Some genes/sensors are sensitive to expression level—avoid assuming “more is better.”
• Interpretation drift: Reporters show expression, not necessarily functional effect—pair with functional readouts.
• Genetic context: Cre/Flp effects depend on the target locus and recombination efficiency.

Handling note:

• Form: Frozen liquid — plan thawing/mixing accordingly and avoid repeated freeze-thaw where possible.
• Buffer: PBS — confirm compatibility with your injection/assay buffer requirements.
• Storage: -80°C — aliquot on first thaw when feasible to preserve titer/activity.

What it means: Sensor/Actuator indicates an encoded sensor (reports activity/state) or actuator (modulates activity) included in the vector design. The value shown here is Cre.

How to interpret here: Use Cre to understand what extra experimental inputs you’ll need (light, ligand, guide RNAs, imaging modality) and what readout you can expect. Function category is Recombinases—this helps distinguish ‘readout’ designs (sensors/reporters) from ‘perturbation’ designs (actuators/editors). Targeted expression depends on promoter CMV, cell-type intent Ubiquitous plus the delivery context. Listed applications: In vivo gene delivery, Cre/loxP recombination, Conditional genetics, Lineage tracing—confirm your workflow supports the required stimulus/readout.

Why it matters for buying:

• Experimental prerequisites: Sensors/actuators can require specific hardware (light delivery, imaging) or reagents (ligands).
• Controls: Interpretation is highly control-dependent (light-only, ligand-only, vector-only, non-functional variants).
• Timing and dose: Functional readouts can depend strongly on expression level and expression kinetics.

Practical guidance:

• Plan the full system: Confirm you have compatible optics/filters, stimulation parameters, or ligand protocols before ordering.
• Run calibration pilots: Determine expression timecourse, effective stimulation/ligand dose, and baseline variability.
• Use matched negative controls: Include inactive or null constructs when possible to separate delivery effects from actuator/sensor effects.

What to watch out for:

• Off-target stimulus effects: Light or ligand can affect biology independent of the actuator—controls are essential.
• Phototoxicity/heat: Optogenetic/imaging workflows can perturb tissue; optimize intensity and duration.
• Expression burden: High expression of sensors/actuators can stress cells or change physiology—dose carefully.

Handling note:

• Form: Frozen liquid — plan thawing/mixing accordingly and avoid repeated freeze-thaw where possible.
• Buffer: PBS — confirm compatibility with your injection/assay buffer requirements.
• Storage: -80°C — aliquot on first thaw when feasible to preserve titer/activity.

What it means: Function summarizes the intended experimental role of this AAV design (e.g., control, labeling, perturbation). The value shown here is Recombinases.

How to interpret here: Use Recombinases to decide whether this is an appropriate experimental control or an active biology-changing reagent. Function categories are often broader than the specific payload, so cross-check with the transgene and promoter. Transgene is Cre—this is the most concrete indicator of mechanism (e.g., reporter vs recombinase vs effector). Listed applications: In vivo gene delivery, Cre/loxP recombination, Conditional genetics, Lineage tracing—align the function with your workflow (in vivo delivery vs in vitro benchmarking).

Why it matters for buying:

• Study design: Function determines whether the vector is a control, a readout tool, or an intervention.
• Interpretability: Using the right control reduces ambiguity (delivery/capsid effects vs payload effects).
• Cost efficiency: Selecting an appropriate control vector can save time by preventing confounded experiments.

Practical guidance:

• Choose controls that match: For in vivo work, match serotype and promoter when using a control vector so delivery and expression context are comparable.
• Define your readout: Decide whether you need a reporter to verify expression distribution and kinetics.
• Document dosing: Record vg dose, route, and timepoint so results are comparable and reproducible.

What to watch out for:

• Control mismatch: A control with a different promoter/serotype can mislead by changing transduction patterns.
• Reporter effects: Even ‘neutral’ reporters can affect cell physiology at very high expression; interpret carefully.
• Context dependence: Function categories don’t guarantee outcomes—validate in your model.

Handling note:

• Form: Frozen liquid — plan thawing/mixing accordingly and avoid repeated freeze-thaw where possible.
• Buffer: PBS — confirm compatibility with your injection/assay buffer requirements.
• Storage: -80°C — aliquot on first thaw when feasible to preserve titer/activity.

What it means: Cell Type indicates the intended or typical cell population for expression/readout. The value shown here is Ubiquitous.

How to interpret here: Use Ubiquitous as a guide for expected expression patterns, but treat cell-type targeting as a combination of promoter choice, capsid/serotype tropism, route, and dose—not a single-field guarantee. “Ubiquitous” suggests the design is intended for broad expression; real-world expression still depends on serotype, route, dose, and the biological context. Promoter is CMV—promoter is the primary driver of cell-type restriction when applicable. Serotype is AAV2/4—serotype affects which cells are transduced; a cell-type promoter won’t help if the capsid doesn’t reach/enter the target cells. Expression regulation is Constitutive—regulation can affect when and where expression is observed. Listed applications: In vivo gene delivery, Cre/loxP recombination, Conditional genetics, Lineage tracing—plan validation (marker co-staining, reporter imaging) in the relevant tissue and timepoint.

Why it matters for buying:

• Specificity: Correct cell-type targeting reduces off-target expression and improves interpretability.
• Efficiency: Cell populations vary in transduction efficiency; design and route choices affect required dose and success rate.
• Controls: Cell-type assumptions drive what controls and validation markers you need.

Practical guidance:

• Validate cell identity: Use marker co-localization (immunostaining or genetic reporters) to confirm which cells express the payload.
• Optimize delivery: Route, dose, and timing can shift cell-type distribution—pilot studies are highly recommended.
• Plan background controls: Include vector-only/null controls and assess off-target expression in non-target cell populations.

What to watch out for:

• Species and age effects: Tropism and promoter behavior can vary across species, strain, and developmental stage.
• Inflammation/disease: Disease states can change promoter activity and cell susceptibility to transduction.
• Over-interpretation: ‘Cell type’ labels are guidance; confirm empirically in your own model.

Handling note:

• Form: Frozen liquid — plan thawing/mixing accordingly and avoid repeated freeze-thaw where possible.
• Buffer: PBS — confirm compatibility with your injection/assay buffer requirements.
• Storage: -80°C — aliquot on first thaw when feasible to preserve titer/activity.